In the UK and globally children are suffering unnecessarily because their health needs are routinely left behind in medical research and development (R&D). A new Independent Child-Lens Taskforce on Health Research, Innovation and Investment has launched to address decades of systemic under-investment in children's health R&D.
Just 1.6% of healthcare venture capital is directed towards child health innovation globally.
Children represent 25% of the global population yet their health needs are systemically underserved.
Globally, 50% of paediatric medicines used in hospitals are “off-label”, which means they are not officially approved by regulatory authorities, creating safety risks.
Rare diseases disproportionately affect children, but less than 10% of rare disease therapies are tested in paediatric populations.
Our Taskforce will focus on developing practical, evidence-based recommendations to advance investment in UK paediatric health R&D.
We hope this approach will improve access and outcomes for young patients across the UK.
The Taskforce was launched on 10th July 2026. With our first face-to-face meeting taking place at the House of Lords in October 2026.
Distinguished members include those from across the UK, Europe, and Internationally.
Contact us to find out more:
Rhian Thomas Turner
Head of Paediatric Research Operations & Strategy, Cardiff & Vale UHB
📧 Rhian.thomas-turner@wales.nhs.uk
